Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 459-471

  Kenny, Hilary A ^a   Leonhardt, Payton ^a   Ladanyi, Andras ^a   Yamada, S Diane ^a   Montag, Anthony ^a   Im, Hae Kyung ^a   Jagadeeswaran, Sujatha ^a   Shaw, David E ^b   Mazar, Andrew P ^c   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; CASPASE 3; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY ATN 658; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; OMENTUM; OVARY CANCER; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551718325     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2258     Document Type: Article

References (40)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43. (Pubitemid 35477371)
5. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008;14:5649-55.
6. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
7. Dass K, Ahmad A, Azmi AS, Sarkar S, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36.
8. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91. (Pubitemid 24275853)
9. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004;23:8486-96. (Pubitemid 39540799)
10. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-met and insulin-like growth factor-1 receptor-mediated migration and invasion and orthotopic tumor grwoth in mice. Cancer Res 2005;17:7775-81. (Pubitemid 41297252)
11. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, et al. β3 -integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009;175:2184-96.
12. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67:1670-80.
13. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer 2007;121:1463-72. (Pubitemid 47328704)
14. Kenny HA, Kaur S, Coussens L, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-79. (Pubitemid 351500430)
15. Abberton KM, Bortolotto SK, Woods AA, Findlay M, Morrison WA, Thompson EW, et al. Myogel, a novel, basement membrane-rich, extracellular matrix derived from skeletal muscle, is highly adipogenic in vivo and in vitro. Cells Tissues Organs 2008;188:347-58.
16. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:2002-7.
17. Casslen B, Gustavsson B, Astedt B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer 1991;27:1445-8.
18. Borgfeldt C, Bendahl PO, Gustavsson B, Långström E, Fernö M, Willén R, et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int J Cancer 2003;107:658-65. (Pubitemid 37296130)
19. Borgfeldt C, Hansson S, Gustavsson B, Måsbäck A, Casslen B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor PAI-1. Int J Cancer 2001;92:497-502. (Pubitemid 32319422)
20. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000;10:372-81.
21. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995;55:3958-63.
22. Mabrouk R, Ali-Labib R. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. Clin Biochem 2003;36:537-43. (Pubitemid 37244016)
23. Chambers SK, Ivins CM, Carcangiu ML. Urokinase-type plasminogen activator in epithelial ovarian cancer: a poor prognostic factor, associated with advanced stage. Int J Gynecol Cancer 1998;8:242-50. (Pubitemid 28317962)
24. Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol 2009;114:265-72.
25. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2010;2:301-14.
26. Tarui T, Andronicos N, Czekay RP, Mazar AP, Bdeir K, Parry GC, et al. Critical role of integrin α5β1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem 2003;278:29863-72. (Pubitemid 36962374)
27. Wei Y, Tang C, Kim Y, Robillard L, Zhang F, Kugler MC, et al. Urokinase receptors are required for α5β1 integrin-mediated signaling in tumor cells. J Biol Chem 2007;282: 3929-39. (Pubitemid 47084483)
28. Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, et al. An anti-urokinase plasminogen activator antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 2010;12:778-88.
29. StoppelliMP, Corti A, Soffientini A, Cassanni G, Blasi F, Assoian R. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A 1985;82:4939-43. (Pubitemid 15249921)
30. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92. (Pubitemid 15151884)
31. Frederick PJ, Straughn JM, Alvarez RD, Buchsbaum HJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009;113:384-90.
32. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predicitive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39. (Pubitemid 37204044)
33. Sato S, Kopitz C, Schmalix WF, Muehlenweg B, Kessler H, Schmitt M, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002;528:212-6. (Pubitemid 35258026)
34. Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, et al. Development and evaluation of peptidic ligands, targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J in Nucl Med Mol Imaging 2008;35:53-64. (Pubitemid 350234153)
35. de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, Wang Y. Inhibition of urokinase receptor gene expression and cell invasion by antiuPAR DNAzymes in osteosarcoma cells. FEBS J 2005;272:3572-82. (Pubitemid 41021170)
36. Van Buren G 2nd, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, et al. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009;115:3360-8.
37. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-33. (Pubitemid 26154094)
38. Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, et al. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998;16:9-20. (Pubitemid 28122551)
39. Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001;382:789-98. (Pubitemid 32631716)
40. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Downregulation of uPAR and uPA activates caspase mediated apoptosis, inhibits the PI3kinase/AKT pathway. Int J Oncol 2007;31:19-27.